CORE-ABR
Sales sheet Request a demo

Resistance gene

Class A beta-lactamase (KPC / SHV)

Predicts: Carbapenemase (KPC) or ESBL (SHV variants) production. Reported qualitatively as detected or not detected.

Qualitative PCR targetApplied per organism

Mechanism

Serine beta-lactamases. KPC hydrolyzes carbapenems; extended-spectrum SHV variants hydrolyze cephalosporins.

What it removes from the grid

Penicillins, cephalosporins and — for KPC — carbapenems.

What it spares

Ceftazidime-avibactam, meropenem-vaborbactam and imipenem-relebactam inhibit KPC. Ceftolozane-tazobactam does not, so three of four look-alike combinations stay active and one is removed.

A multiplex panel can't say which organism in a mixed specimen carries a detected gene. CORE-ABR applies Class A beta-lactamase (KPC / SHV) only to organisms known to carry it, and only to the agents its mechanism defeats — so a detected gene moves the right cells and spares the rest.

Organisms it is applied to

Klebsiella pneumoniae / oxytocaCommon uropathogens and a leading host of ESBL and KPC carbapenemase genes.Gram-negative bacteria · UTI · Wound · STIEscherichia coliThe most common cause of urinary tract infection, and a frequent organism in wound and intra-abdominal specimens.Gram-negative bacteria · UTI · WoundEnterobacter aerogenes / cloacaeEnterobacterales with chromosomal AmpC. E. aerogenes has been renamed Klebsiella aerogenes; many panels still report the…Gram-negative bacteria · UTI · Wound · STICitrobacter freundiiAn Enterobacterales species that carries a chromosomal AmpC beta-lactamase.Gram-negative bacteria · UTI · Wound · STIPseudomonas aeruginosaA non-fermenting gram-negative bacillus common in chronic wounds and complicated UTI, with a long list of intrinsic resi…Gram-negative bacteria · UTI · Wound · STI

Coding

Z16.12 or Z16.19 depending on the enzyme and documentation. CORE-ABR adds resistance findings as supporting codes, not primary, and prints the rationale on the report.

Tagged

Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.